First National Bank of Omaha’s Ascendis Pharma A/S ASND Stock Holding History

First National Bank of Omaha’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.3M	Buy	10,524 +581	+6%	+$130K	0.07%	256
2025 Q4	$2.08M	Buy	+9,943	New	+$2.05M	0.06%	270

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First National Bank of Omaha's ASND Position: Q1 2026 in Review

First National Bank of Omaha increased its Ascendis Pharma A/S (ASND) stake by 5.8% in Q1 2026, buying an estimated $130K and bringing the position to 10,524 shares worth $2.3M. The position accounts for 0.07% of the portfolio, ranked #256.

First National Bank of Omaha first reported a position in ASND in Q4 2025 and has held it in 2 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

First National Bank of Omaha held 10,524 shares of Ascendis Pharma A/S worth $2.3M as of Q1 2026.
First National Bank of Omaha bought 581 Ascendis Pharma A/S shares in Q1 2026, an estimated $130K.
Ascendis Pharma A/S made up 0.07% of First National Bank of Omaha's portfolio in Q1 2026, its #256 holding.
First National Bank of Omaha first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 2 quarters since.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on First National Bank of Omaha's 13F filing for Q1 2026, filed 11 May 2026.